Baxter International Inc (BAX) 70.39 $BAX
Baxter gene therapy safety trial OK so far but one of six patients showed elevated liver enzymes
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 4:10PM CST
BAX: 70.39 (+0.31)
Baxter Provides Progress Update on Gene Therapy Program, Including Phase I/II Clinical Trial of BAX 335, Investigational Gene Therapy Treatment for Hemophilia B
Business Wire - Thu Feb 12, 3:30PM CST
Baxter International Inc. (NYSE:BAX) today provided an update on its gene therapy program, including progress on the Phase I/II open-label clinical trial assessing the safety and optimal dosing level of BAX 335, an investigational factor IX (FIX) gene therapy treatment for hemophilia B, during a sponsored symposium at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland.
BAX: 70.39 (+0.31)
Baxter Announces Positive Data for BAX 855; Competition Rife - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:40PM CST
Baxter International Inc. (BAX) recently disclosed additional efficacy and safety data from its Phase III pivotal study evaluating BAX 855 which is used to treat patients with hemophilia A.
NVO: 43.76 (+0.61), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
'Opportunity Strategy' - 6 Months Of Trading Rationale And Analysis
Grey Owl Capital - Seeking Alpha - Thu Feb 12, 1:01AM CST
"Never think that lack of variability is stability. Don't confuse lack of volatility with stability, ever." - Nassim Nicholas Taleb Over the past seven months the price of oil has plunged from a peak above $100/barrel to the mid-$40s...
LUK: 23.50 (-0.01), DNOW: 25.64 (+0.70), EXC: 33.51 (-0.93), UPL: 15.67 (+0.84), NOV: 53.36 (+0.80), POST: 48.62 (-0.25), COG: 28.10 (+0.18), BAX: 70.39 (+0.31), AAL: 48.39 (+0.51), LH: 116.90 (+0.06), ENB: 49.37 (-0.22), VWO: 41.78 (+0.42), BRG: 13.65 (+0.31), BRK.B: 148.34 (-1.45), AAPL: 127.08 (+0.62)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Baxter Presents Additional Data from Pivotal Study of BAX 855, Extended Half-Life Investigational Recombinant FVIII Based on ADVATE for Hemophilia A
Business Wire - Wed Feb 11, 8:00AM CST
Baxter International Inc. (NYSE:BAX) today presented additional efficacy and safety data from the Phase III pivotal study of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)] at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland.
BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
'Mad Money' Lightning Round: Stop Fretting and Buy, Buy, Buy Sirius XM
at The Street - Wed Feb 11, 5:00AM CST
Cramer says stick with Taser and take UnitedHealth or Humana over HMS Holdings.
BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), TASR: 26.96 (-0.42), HMSY: 20.00 (+0.38), SIRI: 3.83 (-0.07), REGN: 402.40 (+0.66), HUM: 152.67 (-1.06), CELG: 115.88 (+0.16)
Baxter Needs To Split Up - Cramer's Lightning Round (2/10/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Wed Feb 11, 4:28AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, February 10. Bullish Calls: Achillion Pharmaceuticals (NASDAQ: ACHN ): " We have said it's a decent spec off of another Hep C," said Cramer....
CI: 114.47 (-0.51), BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), HMSY: 20.00 (+0.38), TASR: 26.96 (-0.42), SIRI: 3.83 (-0.07), REGN: 402.40 (+0.66), HUM: 152.67 (-1.06), CELG: 115.88 (+0.16)
Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News
at The Street - Tue Feb 10, 7:35PM CST
With no distractions, the U.S stock market rallied on a slew of terrific company news.
BIIB: 391.66 (-0.45), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), HOT: 78.55 (+0.67), HUM: 152.67 (-1.06), SBUX: 91.58 (-0.24), SAVE: 79.32 (-0.80), MAT: 27.61 (+0.17), CMG: 674.89 (+4.60), TASR: 26.96 (-0.42), REGN: 402.40 (+0.66), SIRI: 3.83 (-0.07), KO: 41.99 (-0.18), HAS: 62.74 (+0.58), DIS: 104.17 (+0.59), ALKS: 71.40 (-1.89), MAS: 26.45 (+0.02), ARO: 3.63 (+0.04), CELG: 115.88 (+0.16), URBN: 38.47 (+0.27), BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), GM: 37.62 (-0.40), YELP: 47.53 (-0.10), HMSY: 20.00 (+0.38)
Baxter to Present at Cowen & Company's 35th Annual Health Care Conference
Business Wire - Tue Feb 10, 3:15PM CST
Baxter International Inc. (NYSE: BAX) announced today that it will present at Cowen & Company's 35th Annual Health Care Conference on Monday, March 2, 2015 at 2:30 p.m. (CT).
BAX: 70.39 (+0.31)
Baxter International A Holding Of Latest 13F Filers
DividendChannel.com - Tue Feb 10, 1:14PM CST
At Holdings Channel, we have reviewed the latest batch of the 23 most recent 13F filings for the 12/31/2014 reporting period, and noticed that Baxter International Inc. was held by 8 of these funds.
BAX: 70.39 (+0.31)
Here Is Why We Believe CTI BioPharma's PERSIST-1 Trial Will Be Successful
Probio Invest - at Seeking Alpha - Tue Feb 10, 10:23AM CST
BAX: 70.39 (+0.31), INCY: 75.94 (+0.28), CTIC: 2.23 (-0.02), SNY: 49.42 (+0.82)
Watch for Baxter International to Potentially Rebound After Falling 1.76% Yesterday
Comtex SmarTrend(R) - Mon Feb 09, 4:17PM CST
Baxter International (NYSE:BAX) traded in a range yesterday that spanned from a low of $69.33 to a high of $70.90. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $69.90 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BAX: 70.39 (+0.31)
Baxter International Falls 1.76% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Feb 09, 4:17PM CST
Baxter International (NYSE:BAX) traded in a range yesterday that spanned from a low of $69.33 to a high of $70.90. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $69.90 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BAX: 70.39 (+0.31)
U.S. Market for Infusion Therapy Devices 2015 (Executive Summary)
M2 - Mon Feb 09, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/3jtjsm/u_s_market_for) has announced the addition of the "U.S. Market for Infusion Therapy Devices 2015 (Executive Summary)" report to their offering. This market includes infusion pumps, intravenous (IV) sets, and needleless connectors (NLCs). The infusion pump market is further divided into segments for large volume, syringe, patient-controlled analgesia (PCA), electronic ambulatory and disposable ambulatory infusion pumps. Main Markets Covered: - Infusion Pump Market - Intravenous Set Market - Needleless Connector Market - Anti-reflux neutral displacement needleless connectors Companies Mentioned - B. Braun - Baxter International - Carefusion - Hospira - ICU Medical - Smiths Medical For more information visit http://www.researchandmarkets.com/research/3j...market_for
ICUI: 88.98 (+0.42), BAX: 70.39 (+0.31)
7 Companies We'd Buy and Hold for the Next 20 Years
Motley Fool Staff - Motley Fool - Fri Feb 06, 2:11PM CST
At The Motley Fool, we take a long-term view on investing. With that in mind, we asked seven of our analysts for their favorite stocks to hold for the next 20 years and beyond. Here's what they had to say. One company I'm interested in buying and...
BLUE: 90.70 (+0.93), TD: 44.57 (+0.14), PFE: 34.64 (-0.23), MO: 54.76 (-0.78), WM: 51.29 (-1.41), CELG: 115.88 (+0.16), PM: 82.87 (-0.82), V: 269.63 (-1.28), BAX: 70.39 (+0.31), AGIO: 118.55 (+0.11), AAPL: 127.08 (+0.62), MA: 87.14 (-0.38)
U.S. Market for Infusion Therapy Devices 2015
M2 - Fri Feb 06, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/l949rj/u_s_market_for) has announced the addition of the "U.S. Market for Infusion Therapy Devices 2015" report to their offering. The infusion therapy device market was disrupted by product recalls affecting a significant proportion of installed base units. However, newer pump systems that incorporate additional features, such as wireless capabilities and drug libraries, will enhance patient safety and drive growth in the market. Unit sales of premium-priced pump systems will contribute to overall growth in the infusion therapy device market. The segments comprising the infusion therapy device market experienced differing growth rates in 2014. A determining factor for growth rates was the increasing emphasis on patient safety. As a result, ASPs for infusion pumps will increase as manufacturers incorporate more sophisticated software that allows practitioners to administer the correct dosage and medication to the right patient. Integration with electronic medical records (EMRs) and wireless capabilities are important drivers in the infusion pump market. However, healthcare expenditure reductions have led to a decline in hospitals beds and a shift towards non-acute settings. Sales of IV sets and needleless connectors remain a significant source of revenues for companies that are able to rely on their presence in the infusion pump market to sell related accessories. While the ASP for a pump is significantly higher than for an IV set or a connector, a pump is a one-time purchase. Recent experience with recalls has illustrated the challenges associated with maintaining a large installed base of pumps. The needleless connector market is heavily dependent on clinical results and practitioner preference. Problems associated with positive displacement devices have led to a trend towards the increasing use of neutral displacement devices, which is expected to persist over the forecast period. Key Topics Covered: List Of Figures List Of Charts 1. Executive Summary 2. Research Methodology 3. U.S. Infusion Therapy Device Market Overview 4. Infusion Pump Market 5. Intravenous Set Market 6. Needleless Connector Market Companies Mentioned - B. Braun - Baxter International - Carefusion - Hospira - ICU Medical - Smiths Medical For more information visit http://www.researchandmarkets.com/research/l9...market_for
ICUI: 88.98 (+0.42), BAX: 70.39 (+0.31)
Baxter International Rises 1.84% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Feb 05, 4:17PM CST
Baxter International (NYSE:BAX) traded in a range yesterday that spanned from a low of $70.70 to a high of $71.82. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $70.91 on volume of 3.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BAX: 70.39 (+0.31)
After Yesterday's Rally of 1.84% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Feb 05, 4:16PM CST
Baxter International (NYSE:BAX) traded in a range yesterday that spanned from a low of $70.70 to a high of $71.82. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $70.91 on volume of 3.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BAX: 70.39 (+0.31)
Baxter gene therapy safety trial OK so far but one of six patients showed elevated liver enzymes
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 4:10PM CST
BAX: 70.39 (+0.31)
Baxter Provides Progress Update on Gene Therapy Program, Including Phase I/II Clinical Trial of BAX 335, Investigational Gene Therapy Treatment for Hemophilia B
Business Wire - Thu Feb 12, 3:30PM CST
Baxter International Inc. (NYSE:BAX) today provided an update on its gene therapy program, including progress on the Phase I/II open-label clinical trial assessing the safety and optimal dosing level of BAX 335, an investigational factor IX (FIX) gene therapy treatment for hemophilia B, during a sponsored symposium at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland.
BAX: 70.39 (+0.31)
Baxter Announces Positive Data for BAX 855; Competition Rife - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:40PM CST
Baxter International Inc. (BAX) recently disclosed additional efficacy and safety data from its Phase III pivotal study evaluating BAX 855 which is used to treat patients with hemophilia A.
NVO: 43.76 (+0.61), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
'Opportunity Strategy' - 6 Months Of Trading Rationale And Analysis
Grey Owl Capital - Seeking Alpha - Thu Feb 12, 1:01AM CST
"Never think that lack of variability is stability. Don't confuse lack of volatility with stability, ever." - Nassim Nicholas Taleb Over the past seven months the price of oil has plunged from a peak above $100/barrel to the mid-$40s...
LUK: 23.50 (-0.01), DNOW: 25.64 (+0.70), EXC: 33.51 (-0.93), UPL: 15.67 (+0.84), NOV: 53.36 (+0.80), POST: 48.62 (-0.25), COG: 28.10 (+0.18), BAX: 70.39 (+0.31), AAL: 48.39 (+0.51), LH: 116.90 (+0.06), ENB: 49.37 (-0.22), VWO: 41.78 (+0.42), BRG: 13.65 (+0.31), BRK.B: 148.34 (-1.45), AAPL: 127.08 (+0.62)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Baxter Presents Additional Data from Pivotal Study of BAX 855, Extended Half-Life Investigational Recombinant FVIII Based on ADVATE for Hemophilia A
Business Wire - Wed Feb 11, 8:00AM CST
Baxter International Inc. (NYSE:BAX) today presented additional efficacy and safety data from the Phase III pivotal study of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)] at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland.
BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
'Mad Money' Lightning Round: Stop Fretting and Buy, Buy, Buy Sirius XM
at The Street - Wed Feb 11, 5:00AM CST
Cramer says stick with Taser and take UnitedHealth or Humana over HMS Holdings.
BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), TASR: 26.96 (-0.42), HMSY: 20.00 (+0.38), SIRI: 3.83 (-0.07), REGN: 402.40 (+0.66), HUM: 152.67 (-1.06), CELG: 115.88 (+0.16)
Baxter Needs To Split Up - Cramer's Lightning Round (2/10/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Wed Feb 11, 4:28AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, February 10. Bullish Calls: Achillion Pharmaceuticals (NASDAQ: ACHN ): " We have said it's a decent spec off of another Hep C," said Cramer....
CI: 114.47 (-0.51), BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), HMSY: 20.00 (+0.38), TASR: 26.96 (-0.42), SIRI: 3.83 (-0.07), REGN: 402.40 (+0.66), HUM: 152.67 (-1.06), CELG: 115.88 (+0.16)
Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News
at The Street - Tue Feb 10, 7:35PM CST
With no distractions, the U.S stock market rallied on a slew of terrific company news.
BIIB: 391.66 (-0.45), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), HOT: 78.55 (+0.67), HUM: 152.67 (-1.06), SBUX: 91.58 (-0.24), SAVE: 79.32 (-0.80), MAT: 27.61 (+0.17), CMG: 674.89 (+4.60), TASR: 26.96 (-0.42), REGN: 402.40 (+0.66), SIRI: 3.83 (-0.07), KO: 41.99 (-0.18), HAS: 62.74 (+0.58), DIS: 104.17 (+0.59), ALKS: 71.40 (-1.89), MAS: 26.45 (+0.02), ARO: 3.63 (+0.04), CELG: 115.88 (+0.16), URBN: 38.47 (+0.27), BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), GM: 37.62 (-0.40), YELP: 47.53 (-0.10), HMSY: 20.00 (+0.38)
Baxter to Present at Cowen & Company's 35th Annual Health Care Conference
Business Wire - Tue Feb 10, 3:15PM CST
Baxter International Inc. (NYSE: BAX) announced today that it will present at Cowen & Company's 35th Annual Health Care Conference on Monday, March 2, 2015 at 2:30 p.m. (CT).
BAX: 70.39 (+0.31)
Baxter International A Holding Of Latest 13F Filers
DividendChannel.com - Tue Feb 10, 1:14PM CST
At Holdings Channel, we have reviewed the latest batch of the 23 most recent 13F filings for the 12/31/2014 reporting period, and noticed that Baxter International Inc. was held by 8 of these funds.
BAX: 70.39 (+0.31)
Here Is Why We Believe CTI BioPharma's PERSIST-1 Trial Will Be Successful
Probio Invest - at Seeking Alpha - Tue Feb 10, 10:23AM CST
BAX: 70.39 (+0.31), INCY: 75.94 (+0.28), CTIC: 2.23 (-0.02), SNY: 49.42 (+0.82)
Watch for Baxter International to Potentially Rebound After Falling 1.76% Yesterday
Comtex SmarTrend(R) - Mon Feb 09, 4:17PM CST
Baxter International (NYSE:BAX) traded in a range yesterday that spanned from a low of $69.33 to a high of $70.90. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $69.90 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BAX: 70.39 (+0.31)
Baxter International Falls 1.76% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Feb 09, 4:17PM CST
Baxter International (NYSE:BAX) traded in a range yesterday that spanned from a low of $69.33 to a high of $70.90. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $69.90 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BAX: 70.39 (+0.31)
U.S. Market for Infusion Therapy Devices 2015 (Executive Summary)
M2 - Mon Feb 09, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/3jtjsm/u_s_market_for) has announced the addition of the "U.S. Market for Infusion Therapy Devices 2015 (Executive Summary)" report to their offering. This market includes infusion pumps, intravenous (IV) sets, and needleless connectors (NLCs). The infusion pump market is further divided into segments for large volume, syringe, patient-controlled analgesia (PCA), electronic ambulatory and disposable ambulatory infusion pumps. Main Markets Covered: - Infusion Pump Market - Intravenous Set Market - Needleless Connector Market - Anti-reflux neutral displacement needleless connectors Companies Mentioned - B. Braun - Baxter International - Carefusion - Hospira - ICU Medical - Smiths Medical For more information visit http://www.researchandmarkets.com/research/3j...market_for
ICUI: 88.98 (+0.42), BAX: 70.39 (+0.31)
7 Companies We'd Buy and Hold for the Next 20 Years
Motley Fool Staff - Motley Fool - Fri Feb 06, 2:11PM CST
At The Motley Fool, we take a long-term view on investing. With that in mind, we asked seven of our analysts for their favorite stocks to hold for the next 20 years and beyond. Here's what they had to say. One company I'm interested in buying and...
BLUE: 90.70 (+0.93), TD: 44.57 (+0.14), PFE: 34.64 (-0.23), MO: 54.76 (-0.78), WM: 51.29 (-1.41), CELG: 115.88 (+0.16), PM: 82.87 (-0.82), V: 269.63 (-1.28), BAX: 70.39 (+0.31), AGIO: 118.55 (+0.11), AAPL: 127.08 (+0.62), MA: 87.14 (-0.38)
U.S. Market for Infusion Therapy Devices 2015
M2 - Fri Feb 06, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/l949rj/u_s_market_for) has announced the addition of the "U.S. Market for Infusion Therapy Devices 2015" report to their offering. The infusion therapy device market was disrupted by product recalls affecting a significant proportion of installed base units. However, newer pump systems that incorporate additional features, such as wireless capabilities and drug libraries, will enhance patient safety and drive growth in the market. Unit sales of premium-priced pump systems will contribute to overall growth in the infusion therapy device market. The segments comprising the infusion therapy device market experienced differing growth rates in 2014. A determining factor for growth rates was the increasing emphasis on patient safety. As a result, ASPs for infusion pumps will increase as manufacturers incorporate more sophisticated software that allows practitioners to administer the correct dosage and medication to the right patient. Integration with electronic medical records (EMRs) and wireless capabilities are important drivers in the infusion pump market. However, healthcare expenditure reductions have led to a decline in hospitals beds and a shift towards non-acute settings. Sales of IV sets and needleless connectors remain a significant source of revenues for companies that are able to rely on their presence in the infusion pump market to sell related accessories. While the ASP for a pump is significantly higher than for an IV set or a connector, a pump is a one-time purchase. Recent experience with recalls has illustrated the challenges associated with maintaining a large installed base of pumps. The needleless connector market is heavily dependent on clinical results and practitioner preference. Problems associated with positive displacement devices have led to a trend towards the increasing use of neutral displacement devices, which is expected to persist over the forecast period. Key Topics Covered: List Of Figures List Of Charts 1. Executive Summary 2. Research Methodology 3. U.S. Infusion Therapy Device Market Overview 4. Infusion Pump Market 5. Intravenous Set Market 6. Needleless Connector Market Companies Mentioned - B. Braun - Baxter International - Carefusion - Hospira - ICU Medical - Smiths Medical For more information visit http://www.researchandmarkets.com/research/l9...market_for
ICUI: 88.98 (+0.42), BAX: 70.39 (+0.31)
Baxter International Rises 1.84% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Feb 05, 4:17PM CST
Baxter International (NYSE:BAX) traded in a range yesterday that spanned from a low of $70.70 to a high of $71.82. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $70.91 on volume of 3.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BAX: 70.39 (+0.31)
After Yesterday's Rally of 1.84% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Feb 05, 4:16PM CST
Baxter International (NYSE:BAX) traded in a range yesterday that spanned from a low of $70.70 to a high of $71.82. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $70.91 on volume of 3.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BAX: 70.39 (+0.31)
